Mental health disorders have long been a significant global challenge, affecting millions of individuals and placing an immense burden on healthcare systems worldwide. Despite substantial investments in research and development,…
Read More
In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is…
Read More
Once stigmatized, mental health conditions like anxiety, depression, schizophrenia, and post-traumatic stress disorder are now gaining recognition in society thanks to years of research that have enabled us to identify…
Read More
Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan. Plus, news about Xencor, Otsuka, Typewriter Therapeutics, Cassava Sciences, Enveric Biosciences, Viking Therapeutics and Janux…
Read More
This week Anne Donohoe and Nick Opich talk to Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for…
Read More
Enveric Biosciences stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. Full Article >>
Read More
Enveric Biosciences, a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule therapeutics for depression, anxiety and addiction disorders treatment has signed three non-binding term sheets with another (undisclosed) biotechnology company…
Read More
Enveric Biosciences Inc. said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachusetts-based company didn't disclose the amount. The divested portfolio includes patents…
Read More
Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue to focus and invest in the development of…
Read More
Enveric Biosciences announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI). The compounds span seven distinct molecule…
Read More
